GATA3 and breast cancer: Furthermore, GATA3 expression was associated with a better OS of BC patients with luminal B intrinsic subtype (median survival 261 vs. 166 months for GATA3+ vs. GATA3–, HR 0.64, 95% CI: 0.42 to 0.97, p = 0.036), but not with the other molecular subtypes (Figure 5).